Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant
Open Access
- 7 April 2020
- Vol. 12 (4), 901
- https://doi.org/10.3390/cancers12040901
Abstract
Targeted therapies have improved the outcome of cancer, but their efficacy is intrinsically limited by the emergence of subclones with a mutation in the gene encoding the target protein. A few examples of collateral sensitivity have demonstrated that the conformational changes induced by these mutations can create unexpected sensitivity to other kinase inhibitors, but whether this concept can be generalized is unknown. Here is described the development of a model to screen a library of kinase inhibitors for collateral sensitivity drugs active on the Bruton Tyrosine Kinase (BTK) protein with the ibrutinib resistance mutation C481S. First, we demonstrate that overexpression of the constitutively active mutant of BTK harboring the E41K mutation in Ba/F3 cells creates an oncogenic addiction to BTK. Then, we have exploited this phenotype to perform a screen of a kinase inhibitor library on cells with or without the ibrutinib resistance mutation. The BTK inhibitors showed the expected sensitivity profile, but none of the drugs tested had a specific activity against the C481S mutant of BTK, suggesting that extending the collateral sensitivity paradigm to all kinases targeted by cancer therapy might not be trivial.This publication has 16 references indexed in Scilit:
- Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabBlood, 2019
- Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell MalignanciesTargeted Oncology, 2019
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2017
- Exploiting Temporal Collateral Sensitivity in Tumor Clonal EvolutionCell, 2016
- Resensitization to Crizotinib by the LorlatinibALKResistance Mutation L1198FThe New England Journal of Medicine, 2016
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinibBlood, 2015
- Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationNature, 2015
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibThe New England Journal of Medicine, 2014
- Targeting pathological B cell receptor signalling in lymphoid malignanciesNature Reviews Drug Discovery, 2013
- Ba/F3 cells and their use in kinase drug discoveryCurrent Opinion in Oncology, 2007